We are live on
!
Find out more
NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.23B
1-Year Est. Return
81.32%
This Fund
S&P 500
This Quarter
Est. Return
+8.09%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$2.01B
AUM Growth
+$465M
(+30%)
Cap. Flow
+$371M
Cap. Flow
% of AUM
18.41%
Top 10 Holdings %
Top 10 Hldgs %
74.76%
Holding
43
New
8
Increased
4
Reduced
13
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Harmony Biosciences
HRMY
|
+$137M |
| 2 |
Nkarta
NKTX
|
+$82.3M |
| 3 |
CTLT
CATALENT, INC.
CTLT
|
+$67.7M |
| 4 |
INZY
Inozyme Pharma
INZY
|
+$63.8M |
| 5 |
CMPI
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
|
+$27.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$28.5M |
| 2 |
Vaxcyte
PCVX
|
+$9.18M |
| 3 |
Corvus Pharmaceuticals
CRVS
|
+$6.15M |
| 4 |
SI-BONE Inc
SIBN
|
+$5.79M |
| 5 |
ETTX
Entasis Therapeutics Holdings Inc.
ETTX
|
+$2.93M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54.36% |
| 2 | Technology | 7.2% |
| 3 | Communication Services | 5.36% |
| 4 | Financials | 5.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vanguard Morningstar Total Stock Market ETF
VTI
$646B
| $523M | 25.96% |
3,070,400
| – | – |
|
|
2
Apple
AAPL
$4.97T
| $145M | 7.2% |
1,252,104
-260,800
| -17% | -$28.5M |
|
|
CTLT
3
DELISTED
CATALENT, INC.
CTLT
| $139M | 6.91% |
1,626,000
+801,261
| +97% | +$67.7M |
|
|
4
Harmony Biosciences
HRMY
$2.08B
| $127M | 6.32% |
+3,754,973
| New | +$137M |
|
5
Cable One
CABO
$237M
| $108M | 5.36% |
57,291
| – | – |
|
6
Inogen
INGN
$174M
| $103M | 5.11% |
3,549,320
-1
| -0% | -$31 |
|
7
Medtronic
MDT
$112B
| $103M | 5.1% |
988,136
| – | – |
|
8
Brookfield
BN
$102B
| $102M | 5.04% |
5,738,048
| – | – |
|
|
9
Nkarta
NKTX
$152M
| $84M | 4.17% |
+2,793,864
| New | +$82.3M |
|
|
MORF
10
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $72.3M | 3.59% |
2,645,446
| – | – |
|
|
INZY
11
DELISTED
Inozyme Pharma
INZY
| $67.5M | 3.35% |
+2,569,379
| New | +$63.8M |
|
12
Mirum Pharmaceuticals
MIRM
$6.56B
| $47.1M | 2.34% |
2,445,147
| – | – |
|
|
FOLD
13
DELISTED
Amicus Therapeutics
FOLD
| $32.8M | 1.63% |
2,320,026
| – | – |
|
|
14
Vaxcyte
PCVX
$7.65B
| $32.2M | 1.6% |
651,255
-230,643
| -26% | -$9.18M |
|
|
GRTX
15
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $30.8M | 1.53% |
3,409,021
| – | – |
|
|
CMPI
16
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
| $25M | 1.24% |
+2,170,100
| New | +$27.8M |
|
|
SPNE
17
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $24M | 1.19% |
1,677,492
-112,939
| -6% | -$1.37M |
|
|
BPMC
18
DELISTED
Blueprint Medicines
BPMC
| $21.8M | 1.08% |
234,979
-21,788
| -8% | -$1.68M |
|
|
19
SI-BONE Inc
SIBN
$818M
| $16.6M | 0.82% |
698,504
-291,323
| -29% | -$5.79M |
|
20
Protagonist Therapeutics
PTGX
$8.55B
| $15.5M | 0.77% |
794,369
-29,800
| -4% | -$559K |
|
21
Milestone Pharmaceuticals
MIST
$129M
| $15.2M | 0.76% |
2,080,585
| – | – |
|
|
FLXN
22
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $14.6M | 0.73% |
1,403,370
| – | – |
|
23
Insmed
INSM
$22.4B
| $13.8M | 0.69% |
430,107
| – | – |
|
24
Iovance Biotherapeutics
IOVA
$2.04B
| $12.7M | 0.63% |
+384,938
| New | +$11.8M |
|
|
CNST
25
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| $11.7M | 0.58% |
578,134
+141,003
| +32% | +$3.44M |
|
Similar funds
HCA
GX
MP
FLII
IC
CCA
WCM
IA
Novo Holdings A/S's Q3 2020 Portfolio in Review
As of Q3 2020, Novo Holdings A/S held 43 positions worth $2.01B, up 30% from $1.55B the previous quarter. Its ten largest holdings account for 75% of the portfolio.
Novo Holdings A/S deployed $371M of net new capital in Q3 2020, opening 8 new positions and adding to 4 existing holdings. Its largest new stake was Harmony Biosciences: 3,754,973 shares worth $127M.
By sector, the portfolio is most concentrated in Healthcare at 54% of assets, up from 45% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Apple, an estimated $28.5M trimmed.
- Novo Holdings A/S's largest Q3 2020 buy was Harmony Biosciences: 3,754,973 shares worth $127M.
- Novo Holdings A/S added most to CATALENT, INC. in Q3 2020, an estimated $67.7M increase.
- Novo Holdings A/S's biggest Q3 2020 reduction was Apple, cutting an estimated $28.5M.
- Novo Holdings A/S fully exited Neuronetics in Q3 2020, selling an estimated $992K.
- Novo Holdings A/S's ten largest holdings make up 75% of its $2.01B portfolio in Q3 2020.
- Novo Holdings A/S opened 8 new positions and closed 1 in Q3 2020.
- Novo Holdings A/S's portfolio value rose 30% quarter-over-quarter to $2.01B.
Based on Novo Holdings A/S's 13F filing for Q3 2020, filed 16 Nov 2020.